237 related articles for article (PubMed ID: 24956179)
1. Vaccination against δ-retroviruses: the bovine leukemia virus paradigm.
Gutiérrez G; Rodríguez SM; de Brogniez A; Gillet N; Golime R; Burny A; Jaworski JP; Alvarez I; Vagnoni L; Trono K; Willems L
Viruses; 2014 Jun; 6(6):2416-27. PubMed ID: 24956179
[TBL] [Abstract][Full Text] [Related]
2. BLV: lessons on vaccine development.
Abdala A; Alvarez I; Brossel H; Calvinho L; Carignano H; Franco L; Gazon H; Gillissen C; Hamaidia M; Hoyos C; Jacques JR; Joris T; Laval F; Petersen M; Porquet F; Porta N; Ruiz V; Safari R; Suárez Archilla G; Trono K; Willems L
Retrovirology; 2019 Oct; 16(1):26. PubMed ID: 31590667
[TBL] [Abstract][Full Text] [Related]
3. Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.
Rodríguez SM; Florins A; Gillet N; de Brogniez A; Sánchez-Alcaraz MT; Boxus M; Boulanger F; Gutiérrez G; Trono K; Alvarez I; Vagnoni L; Willems L
Viruses; 2011 Jul; 3(7):1210-48. PubMed ID: 21994777
[TBL] [Abstract][Full Text] [Related]
4. Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses.
Sugimoto M; Ohishi K; Ikawa Y
Ther Immunol; 1994 Oct; 1(5):297-301. PubMed ID: 7584504
[TBL] [Abstract][Full Text] [Related]
5. Animal models of bovine leukemia virus and human T-lymphotrophic virus type-1: insights in transmission and pathogenesis.
Lairmore MD
Annu Rev Anim Biosci; 2014 Feb; 2():189-208. PubMed ID: 25384140
[TBL] [Abstract][Full Text] [Related]
6. Reduced humoral immunity and atypical cell-mediated immunity in response to vaccination in cows naturally infected with bovine leukemia virus.
Frie MC; Sporer KR; Wallace JC; Maes RK; Sordillo LM; Bartlett PC; Coussens PM
Vet Immunol Immunopathol; 2016 Dec; 182():125-135. PubMed ID: 27863543
[TBL] [Abstract][Full Text] [Related]
7. Detection of cross-reactive antibody to BLV p24 in sera of human patients infected with HTLV.
Onuma M; Tsukiyama K; Ohya K; Morishima Y; Ohno R
Microbiol Immunol; 1987; 31(2):131-7. PubMed ID: 2885727
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Expression and Latency in BLV and HTLV.
Pluta A; Jaworski JP; Douville RN
Viruses; 2020 Sep; 12(10):. PubMed ID: 32992917
[No Abstract] [Full Text] [Related]
9. Protective effects of a live attenuated bovine leukaemia virus vaccine with deletion in the R3 and G4 genes.
Reichert M; Cantor GH; Willems L; Kettmann R
J Gen Virol; 2000 Apr; 81(Pt 4):965-9. PubMed ID: 10725422
[TBL] [Abstract][Full Text] [Related]
10. Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes.
Cherney TM; Schultz RD
Am J Vet Res; 1996 Jun; 57(6):812-8. PubMed ID: 8725805
[TBL] [Abstract][Full Text] [Related]
11. Short communication: Bovine leukemia virus infection in adult cows does not interfere with foot-and-mouth disease vaccination.
Jaworski JP; Sala JM; Capozzo A
J Dairy Sci; 2018 Dec; 101(12):11247-11250. PubMed ID: 30316588
[TBL] [Abstract][Full Text] [Related]
12. HTLV-I, adult T-cell leukemia, and tropical spastic paraparesis.
Sarin PS
Ann Neurol; 1988; 23 Suppl():S181-4. PubMed ID: 2894811
[TBL] [Abstract][Full Text] [Related]
13. Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits.
Altanerova V; Holicova D; Kucerova L; Altaner C; Lairmore MD; Boris-Lawrie K
Virology; 2004 Nov; 329(2):434-9. PubMed ID: 15518821
[TBL] [Abstract][Full Text] [Related]
14. Bovine Leukaemia Virus: Current Epidemiological Circumstance and Future Prospective.
Marawan MA; Alouffi A; El Tokhy S; Badawy S; Shirani I; Dawood A; Guo A; Almutairi MM; Alshammari FA; Selim A
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834973
[TBL] [Abstract][Full Text] [Related]
15. The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.
Saito M; Tanaka R; Fujii H; Kodama A; Takahashi Y; Matsuzaki T; Takashima H; Tanaka Y
Retrovirology; 2014 Aug; 11():74. PubMed ID: 25163482
[TBL] [Abstract][Full Text] [Related]
16. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
Gessain A; Mahieux R
Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology of bovine leukemia virus.
Schwartz I; Lévy D
Vet Res; 1994; 25(6):521-36. PubMed ID: 7889034
[TBL] [Abstract][Full Text] [Related]
18. Long-term protection against bovine leukaemia virus replication in cattle and sheep.
Kerkhofs P; Gatot JS; Knapen K; Mammerickx M; Burny A; Portetelle D; Willems L; Kettmann R
J Gen Virol; 2000 Apr; 81(Pt 4):957-63. PubMed ID: 10725421
[TBL] [Abstract][Full Text] [Related]
19. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).
Shuh M; Beilke M
Microsc Res Tech; 2005 Nov; 68(3-4):176-96. PubMed ID: 16276549
[TBL] [Abstract][Full Text] [Related]
20. Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination.
Brillowska A; Dabrowski S; Rułka J; Kubiś P; Buzała E; Kur J
Acta Biochim Pol; 1999; 46(4):971-6. PubMed ID: 10824867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
